皮奥格利塔通过减轻由TGF-β诱导的miRNA失调和自功能障碍来保护管上皮细胞在纤维化期间
Anna Manzéger1,2, Gantsetseg Garmaa1, Miklós M Mózes1,2
1Institute of Translational Medicine, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.
International journal of molecular sciences
|November 14, 2023
概括
皮奥利塔是一种PPARγ激动剂,通过恢复自和调节microRNAs,有效地对抗纤维化. 这项研究揭示了其通过向这些关键途径来治疗纤维性病的潜力.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 纤维化是由过度的TGF-β和亲纤维小RNA驱动的,缺乏有效的治疗方法.
- 功能失调的自与纤维化病原发生有关.
- 在纤维化,自和miRNA调节中PPARγ激动剂的作用在很大程度上是未知的.
研究的目的:
- 为了研究皮奥格利塔 (一种PPARγ激动剂) 对脏自和脏纤维化中的miRNA失调的影响.
- 评估皮奥格利塔在纤维化小鼠模型中的治疗潜力.
主要方法:
- 主管状上皮细胞 (PTEC) 用皮奥格利塔和TGF-β1.1进行治疗.
- 一个TGF-β过度表达的小鼠模型被用皮奥格利塔治疗了5周.
- 评估了mRNA和蛋白质表达,上皮细胞转变为介质细胞,以及自标志物.
主要成果:
- 皮奥格利塔减弱的TGF-β诱导的亲纤维细胞标志物,上皮细胞转变为介质细胞,以及PTEC中的miRNA上调.
- 在过度表达TGF-β的小鼠中,pioglitazone治疗显著改善了纤维化和恢复了自功能.
- 炎症和纤维性基因 (Ccl2,Il6,C3,Lgals3) 的脏表达被pioglitazone抑制.
结论:
- 皮奥格利塔可以抵消脏中关键的亲纤维化过程,包括自功能障碍和miRNA失调.
- 这些发现表明pioglitazone作为纤维化的潜在治疗剂.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Glucagon-like Receptor Agonists
332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Oral Hypoglycemic Agents: Glinides
159
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
159
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


